Last reviewed · How we verify
Adalimumab, solution for injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Adalimumab, solution for injection (Adalimumab, solution for injection) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adalimumab, solution for injection TARGET | Adalimumab, solution for injection | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adalimumab, solution for injection CI watch — RSS
- Adalimumab, solution for injection CI watch — Atom
- Adalimumab, solution for injection CI watch — JSON
- Adalimumab, solution for injection alone — RSS
Cite this brief
Drug Landscape (2026). Adalimumab, solution for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-solution-for-injection. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab